Authors
Discussion
Loading...
Member takes
Implication
Clinical guide demonstrates evaluation of therapy benefits versus harms in refractory Crohn disease, highlighting evidence-based clinical decision-making.
Key Points
- Provide a practical framework for interpreting clinical trial literature to quantify therapeutic benefits against adverse drug risks for individual patient care decisions.
- Presented a clinical scenario involving a 35-year-old man with 8-year active, steroid-dependent Crohn disease requiring over 15 mg daily prednisone despite prior surgery and conventional therapies.
- Evaluated the clinical evidence for introducing oral methotrexate while addressing patient concerns regarding expected symptom improvement versus hepatotoxicity risks.
- Highlighted the clinical challenge of translating trial-derived benefit data into quantifiable quality-of-life expectations for individual patients.
- Demonstrated how to balance documented immunosuppressive efficacy against specific drug toxicities such as liver impairment when tapering chronic steroid regimens.
Cite This Study
Gordon Guyatt (1997) studied this question.